GSK appoints president of European consumer healthcare
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has appointed Emma Walmsley as its new president, consumer healthcare Europe, and president designate, worldwide consumer healthcare, effective from 1 May 2010. Ms Walmsley will take up operational responsibility for GSK's European business and brands. She joins from L'Oreal's consumer products business in China, which she headed; prior to this she was global general manager of the Maybelline cosmetics business, based in New York. Ms Walmsley will replace Manfred Scheske, who has served in the role since January 2004. She is also expected to take the role of president, worldwide consumer healthcare, from John Clarke when he retires in the next two years, GSK said. GSK's consumer healthcare division includes OTC medicines, such as analgesics and smoking cessation treatments, as well as products such as toothpaste, nutrition, beverages and dental care.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).